BioSpace News Archive

Alpha Tau Medical Ltd. (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT, announced today that its US pilot trial for skin cancer has completed enrollment as planned.

Cannabics Pharmaceuticals Inc. announced today that Dr. Yonina Tova (MD), internationally recognized Radiation Oncologist has joined the company’s Board of Advisors.

Harrow Health, Inc., an ophthalmic‑focused healthcare company, announced that it will release its financial results for the third quarter and nine months ended September 30, 2021, on Tuesday, November 9, 2021, after the market close.

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company at the forefront of stem cell-based delivery of oncolytic viruses, announced today its selection as a finalist for presentation during the Innovation Showcase at the upcoming sixth annual Oncolytic Virotherapy Summit.

MedinCell will be attending the 12th Jefferies London Healthcare Conference on Tuesday, November 16 and Wednesday, November 17 at the Waldorf Hilton in London.

ADMA Biologics, Inc. announced the closing of its previously announced underwritten public offering of 50 million shares of its common stock at a public offering price of $1.00 per share, in addition to the exercise in full of the underwriters’ option to purchase an additional 7.5 million shares of common stock.

Gritstone bio, Inc. today announced that Gritstone management will participate in five upcoming investor conferences in October, November and December.

Revelation Biosciences Inc. (Revelation), announced today that it engaged Destum Partners Inc. to assist in finding an Ex-US development partner for its therapeutic product candidate REVTx-99, and development partner(s) worldwide for its therapeutic product candidate REVTx-200.

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on Nov 9, 2021 at 8:30 AM Eastern Time to discuss results for its third quarter ended September 30, 2021.

Aziyo Biologics, Inc. (Nasdaq: AZYO), today announced that it was informed by Medtronic that, after conducting a thorough review of customer and patient needs, Medtronic has made the decision to cease distribution of Cellular Bone Matrix (CBM) products.